Literature DB >> 33608027

Improved clinical outcomes after non-invasive oocyte selection and Day 3 eSET in ICSI patients.

Inge Van Vaerenbergh1,2, Tom Adriaenssens3,4, Wim Coucke5, Lisbet Van Landuyt6, Greta Verheyen6, Michaël De Brucker6, Michel Camus6, Peter Platteau6, Michel De Vos3,6, Elien Van Hecke4, André Rosenthal4, Johan Smitz3,4.   

Abstract

BACKGROUND: Non-invasive oocyte quality scoring, based on cumulus gene expression analysis, in combination with morphology scoring, can increase the clinical pregnancy (CPR) and live birth rates (LBR) in Day 3 eSET (elective single embryo transfer) ICSI patients. This was first investigated in a pilot study and is now confirmed in a large patient cohort of 633 patients. It was investigated whether CPR, LBR and time-to-pregnancy could be improved by analyzing the gene expression profile of three predictive genes in the cumulus cells, compared to patients with morphology-based embryo selection only.
METHODS: A large interventional, non-randomized, assessor-blinded cohort study with 633 ICSI patients was conducted in a tertiary fertility center. Non-PCOS patients, 22-39 years old, with good ovarian reserve, were stimulated with HP-hMG using a GnRH antagonist protocol and planned for fresh Day 3 eSET. The cumulus cells from individually denuded oocytes were ranked by a lab-developed cumulus cell test: qRT-PCR for three predictive genes (CAMK1D, EFNB2 and SASH1) and two control genes (UBC, B2M). The embryo selected for transfer was highest ranked from the pool of morphologically transferable Day 3 embryos. Patients in the control (n = 520) and experimental arm (n = 113) were compared for clinical pregnancy and live birth, using a weighted generalized linear model, and time-to-pregnancy using Kaplan-Meier curves.
RESULTS: The CPR was 61% in the experimental arm (n = 113) vs 29% in the control arm (n = 520, p < 0.0001). The LBR in the experimental arm (50%) was significantly higher than in the control arm (27%,p < 0.0001). Time-to-pregnancy was significantly shortened by 3 transfer cycles independent of the number of embryos available on Day 3 (Kaplan-Meier, p < 0.0001). Cumulus cell tested patients < 35 years (n = 65) or ≥ 35 years (n = 48) had a CPR of 62 and 60% respectively (ns). For cumulus cell tested patients with 2, 3-4, or > 4 transferable embryos, the CPR was 66, 52, and 67% (ns) respectively, and thus independent of the number of transferable embryos on Day 3.
CONCLUSIONS: This study provides further evidence of the clinical usefulness of the non-invasive cumulus cell test over time in a larger patient cohort. TRIAL REGISTRATION: Clinicaltrials.gov, NCT03659786 / NCT02962466 (Registered 6Sep2018/11Nov2016, retrospectively registered.

Entities:  

Keywords:  Clinical pregnancy; Cumulus cells; Gene expression; Live birth; Non-invasive; Single embryo transfer

Year:  2021        PMID: 33608027      PMCID: PMC7892761          DOI: 10.1186/s12958-021-00704-5

Source DB:  PubMed          Journal:  Reprod Biol Endocrinol        ISSN: 1477-7827            Impact factor:   5.211


  37 in total

1.  Cumulus-corona gene expression analysis combined with morphological embryo scoring in single embryo transfer cycles increases live birth after fresh transfer and decreases time to pregnancy.

Authors:  T Adriaenssens; I Van Vaerenbergh; W Coucke; I Segers; G Verheyen; E Anckaert; M De Vos; J Smitz
Journal:  J Assist Reprod Genet       Date:  2019-01-09       Impact factor: 3.412

2.  A randomized assessor-blind trial comparing highly purified hMG and recombinant FSH in a GnRH antagonist cycle with compulsory single-blastocyst transfer.

Authors:  Paul Devroey; Antonio Pellicer; Anders Nyboe Andersen; Joan-Carles Arce
Journal:  Fertil Steril       Date:  2012-01-13       Impact factor: 7.329

3.  Blastocyst formation in in vitro fertilization versus intracytoplasmic sperm injection cycles: influence of the fertilization procedure.

Authors:  Lisbet Van Landuyt; Anick De Vos; Hubert Joris; Greta Verheyen; Paul Devroey; André Van Steirteghem
Journal:  Fertil Steril       Date:  2005-05       Impact factor: 7.329

4.  Cumulus cell gene expression predicts better cleavage-stage embryo or blastocyst development and pregnancy for ICSI patients.

Authors:  S Wathlet; T Adriaenssens; I Segers; G Verheyen; H Van de Velde; W Coucke; R Ron El; P Devroey; J Smitz
Journal:  Hum Reprod       Date:  2011-03-03       Impact factor: 6.918

5.  Deliveries and children born after in-vitro fertilisation in Sweden 1982-95: a retrospective cohort study.

Authors:  T Bergh; A Ericson; T Hillensjö; K G Nygren; U B Wennerholm
Journal:  Lancet       Date:  1999-11-06       Impact factor: 79.321

6.  Ranking and selection of MII oocytes in human ICSI cycles using gene expression levels from associated cumulus cells.

Authors:  J Ekart; K McNatty; J Hutton; J Pitman
Journal:  Hum Reprod       Date:  2013-09-15       Impact factor: 6.918

7.  SASH1 is a scaffold molecule in endothelial TLR4 signaling.

Authors:  Shauna M Dauphinee; Ashley Clayton; Angela Hussainkhel; Cindy Yang; Yoo-Jin Park; Megan E Fuller; Josip Blonder; Timothy D Veenstra; Aly Karsan
Journal:  J Immunol       Date:  2013-06-17       Impact factor: 5.422

8.  How do cumulative live birth rates and cumulative multiple live birth rates over complete courses of assisted reproductive technology treatment per woman compare among registries?

Authors:  D De Neubourg; K Bogaerts; C Blockeel; T Coetsier; A Delvigne; F Devreker; M Dubois; N Gillain; S Gordts; C Wyns
Journal:  Hum Reprod       Date:  2015-11-03       Impact factor: 6.918

9.  The International Glossary on Infertility and Fertility Care, 2017.

Authors:  Fernando Zegers-Hochschild; G David Adamson; Silke Dyer; Catherine Racowsky; Jacques de Mouzon; Rebecca Sokol; Laura Rienzi; Arne Sunde; Lone Schmidt; Ian D Cooke; Joe Leigh Simpson; Sheryl van der Poel
Journal:  Fertil Steril       Date:  2017-07-29       Impact factor: 7.329

10.  Worldwide decline of IVF birth rates and its probable causes.

Authors:  N Gleicher; V A Kushnir; D H Barad
Journal:  Hum Reprod Open       Date:  2019-08-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.